| 09/12/2025 15:30 |
Revision of Consolidated Earnings Forecast for the Fiscal Year Ending January 2026 |
| 09/12/2025 15:30 |
Notice Concerning Recording of Non-operating Expenses and Deferred Income Taxes |
| 09/12/2025 15:30 |
Consolidated Financial Results for the Six Months Ended July 31, 2025 [Japanese GAAP] |
| 07/18/2025 15:30 |
Notice on Conclusion of Committed Credit Line Agreement with MUFG Bank, Ltd. |
| 06/25/2025 15:30 |
Notice Regarding Revision of Expected Approval Timing for Partial Changes to AKUUGO(R)Suspension for Intracranial Implantation |
| 06/13/2025 15:30 |
Notice Concerning Recording of Non-operating Expenses, and Deferred Income Taxes |
| 06/13/2025 15:30 |
Consolidated Financial Results for the Three Months Ended April 30, 2025 [Japanese GAAP] |
| 06/12/2025 15:30 |
Notice of Completion of Application for Partial Change Approval of AKUUGO(R) Suspension for Intracranial Implantation |
| 06/09/2025 15:30 |
Notice on Conclusion of Committed Credit Line Agreement with Mizuho Bank, Ltd. |
| 05/30/2025 15:30 |
[Delayed] Keita Mori, Representative Director and President of SanBio, Appointed Chairman of Samurai Biotech Association |
| 04/18/2025 15:30 |
The Yield Results of the Third Commercial Production Run for AKUUGO(R) Suspension for Intracranial Implantation |
| 03/18/2025 15:30 |
Presentation for Financial Results for the Fiscal Year Ending January 31, 2025 |
| 03/17/2025 15:30 |
Notice Concerning Differences between Consolidated Earnings Forecast and Actual Results for the Fiscal Year Ending January 31, 2025 |
| 03/17/2025 15:30 |
Notice Concerning Recording of Non-operating Income, Non-operating Expenses, Extraordinary Gains, and Deferred Income Taxes |
| 03/17/2025 15:30 |
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus |
| 03/17/2025 15:30 |
Consolidated Financial Results for the Fiscal Year Ended January 31, 2025[Japanese GAAP] |
| 02/12/2025 11:00 |
Publication of Results of Cell Implantation Location Analysis from STEMTRA Trial in Neurotrauma Reports |
| 02/06/2025 15:30 |
The Results of the Second Commercial Production Run of AKUUGO(R) |
| 02/05/2025 15:30 |
[Delayed] Conclusion of Contract Manufacturing Agreement with JCR Pharma for Trial Production of AKUUGO |
| 02/04/2025 16:30 |
Determination of Terms and Conditions of Stock Options(Share Acquisition Rights) |
| 02/04/2025 16:30 |
Revision of Consolidated Earnings Forecast for the Fiscal Year Ending January 2025 |
| 01/20/2025 16:35 |
Announcement on Granting Stock Options (Share Acquisition Rights) |
| 01/07/2025 15:30 |
Publication of an Article in Molecular Therapy of SB623 |
| 12/16/2024 15:30 |
Announcement on Acquisition and Cancellation of Stock Options (Share Acquisition Rights) |
| 12/16/2024 15:30 |
Notice Concerning Recording of Non-operating Income, Extraordinary Gains, and Deferred Income Taxes |
| 12/16/2024 15:30 |
Consolidated Financial Results for the Nine Months Ended October 31, 2024 [Japanese GAAP] |
| 12/06/2024 15:30 |
The Yield Results of the Second Commercial Production Run for AKUUGO(R) |
| 10/30/2024 15:00 |
Notice Concerning the Grant of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the United States |
| 09/18/2024 15:00 |
Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending January 31, 2025 |
| 09/17/2024 15:00 |
Notice Concerning Recording of Non-operating Income and Deferred Income Taxes |
